Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check6 days agoChange DetectedThe site footer now identifies the release as v3.8.0 instead of v3.7.2; the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedA site-wide banner announces NIH website updates and a change in terminology from “Artificial Intelligence” to “Super Intelligence.” The site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check34 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1; the page continues to display a 403 error.SummaryDifference0.2%

- Check48 days agoChange DetectedThe study record page now displays a 403 Forbidden message instead of the study details, making the record inaccessible to users visiting the page.SummaryDifference19%

- Check55 days agoChange DetectedThe revision tag was updated from v3.6.6 to v3.7.0, indicating a deployment update; no study content changes are introduced.SummaryDifference0.1%

- Check69 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6, indicating a small update to the site's underlying system.SummaryDifference0.1%

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.